[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

Thalidomide therapy in advanced thyroid cancer

In a recent trial reported from Kentucky, thirteen out seventeen patients with differentiated (i.e papillary or follicular) thyroid cancer (76%) responded to thalidomide therapy. It is regarded that thalidomide owes its anti-cancer therapeutic properties to its inhibition of angiogenesis. Thalidomide has toxicity and if these data hold up in subsequent studies then the pressure will be on to find equivalent or better agents with anti-angiogeneisis activity but with a safer toxicity profile.